Sacubitril/Valsartan

Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure[1][2][3]. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis[4].

Product Specifications

CAS Number

[936623-90-4]

Product Name Alternative

LCZ696

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin Receptor; Apoptosis; Neprilysin

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/LCZ696.html

Purity

99.99

Solubility

DMSO : ≥ 100 mg/mL|H2O : ≥ 50 mg/mL

Smiles

O=C(CCC(O[Na])=O)N([C@H](CC(C=C1)=CC=C1C2=CC=CC=C2)C[C@@H](C)C(OCC)=O)[H].O=C(O[Na])[C@@H](N(C(CCCC)=O)CC3=CC=C(C4=CC=CC=C4C5=NN=NN5[Na])C=C3)C(C)C.O

Molecular Formula

C48H55N6Na3O8.2.5H2O

Molecular Weight

957.99

Precautions

H302, H315, H319, H335

References & Citations

[1]Gu J, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) . J Clin Pharmacol. 2010 Apr;50 (4) :401-14.|[2]von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8 (1) :71-8.|[3]Huo H, et al. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells. PLoS One. 2016 May 12;11 (5) :e0154605.|[4]Ge Q, et al. Feature article: LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabeticcardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis. Exp Biol Med (Maywood) . 2019 Sep;244 (12) :1028-1039.